Shares of Axsome Therapeutics (AXSM) are on the rise on Monday after the company said its AXS-05 “significantly” improved agitation in patients with Alzheimer’s disease in a 366-person Phase 2/3 trial. Commenting on the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3079750/-Axsome-jumps-as-lead-candidate-successful-in-Alzheimers-trial)
previous post